Claris Lifesciences shines on receiving ANDA approval for Levofloxacin Injection in US

07 Jun 2013 Evaluate

Claris Lifesciences is currently trading at Rs. 156.00, up by 1.55 points or 1.00% from its previous closing of Rs. 154.95 on the BSE.

The scrip opened at Rs. 163.45 and has touched a high and low of Rs. 163.45 and Rs. 154.65 respectively. So far 95,000 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 292.20 on 05-Dec-2012 and a 52 week low of Rs. 150.00 on 16-May-2013.

Last one week high and low of the scrip stood at Rs. 166.00 and Rs. 152.00 respectively. The current market cap of the company is Rs. 998 crore.

The promoters holding in the company stood at 62.06% while Institutions and Non-Institutions held 24.15% and 13.79% respectively.

Claris Lifesciences has received an Abbreviated New Drug Application (ANDA) approval for Levofloxacin Injection; having strength of 25mg/ ml in 20 ml vials in the United States of America (US). Levofloxacin Injection is an anti-infective drug administered on adults suffering from infection such as Pneumonia, Acute Bacterial Sinusitis or Complicated Urinary Tract Infection, etc. The intravenous route of administration is considered advantageous to the patient.

Claris is also one of the few injectables companies in India to have its own front end in the US, the company markets its products through its wholly owned subsidiary Claris Lifesciences Inc. The company now has 11 ANDAs approved and has a total filing of 32 ANDAs.

Peers
Company Name CMP
Redington 269.95
Adani Enterprises 2221.80
Amrapali Industries 14.85
Rashi Peripheral 351.40
PDS 370.60
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×